To describe the effects of treatment for 1 year with ranibizumab or bevacizumab on macular morphology and the association of macular morphology with visual acuity (VA) in eyes with neovascular age-related macular degeneration (AMD).
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2026.
All research outputs
#2,908,259
of 34,089,221 outputs
Outputs from Ophthalmology
#951
of 8,788 outputs
Outputs of similar age
#20,956
of 236,873 outputs
Outputs of similar age from Ophthalmology
#13
of 75 outputs
Altmetric has tracked 34,089,221 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,788 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,873 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.
